NCT03721679View on ClinicalTrials.gov

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 25, 2018

Primary Completion Date

January 26, 2021

Study Completion Date

January 26, 2021

Conditions
Solid Cancer
Interventions
BIOLOGICAL

Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months

Same as above

Trial Locations (3)

10029

Icahn School of Medicine at Mount Sinai, New York

20815

Chevy Chase RCCA, Chevy Chase

21601

Bay Hematology Oncology, Easton

Sponsors

Lead Sponsor

Oncovir, Inc.
All Listed Sponsors
collaborator

Chevy Chase Healthcare, Chevy Chase MD

UNKNOWN

collaborator

Mt. Sinai School of Medicine, New York, New York

UNKNOWN

collaborator

Bay Hematology Oncology PA, Easton MD

UNKNOWN

lead

Oncovir, Inc.

INDUSTRY

NCT03721679 - Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 | Biotech Hunter | Biotech Hunter